StockNews.com Downgrades Cellectis (NASDAQ:CLLS) to Hold

Cellectis (NASDAQ:CLLS - Get Free Report) was downgraded by StockNews.com from a "buy" rating to a "hold" rating in a note issued to investors on Wednesday.

Cellectis Price Performance

Shares of NASDAQ:CLLS traded up $0.03 during midday trading on Wednesday, hitting $1.30. The stock had a trading volume of 97,903 shares, compared to its average volume of 138,903. The company's 50-day moving average price is $1.45 and its 200-day moving average price is $1.77. Cellectis has a fifty-two week low of $1.14 and a fifty-two week high of $3.38. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $72.26 million, a P/E ratio of -1.00 and a beta of 3.27.

Cellectis (NASDAQ:CLLS - Get Free Report) last announced its quarterly earnings data on Thursday, March 13th. The biotechnology company reported ($0.16) EPS for the quarter, missing the consensus estimate of $0.06 by ($0.22). The firm had revenue of $33.22 million for the quarter, compared to analyst estimates of $5.90 million. Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. As a group, equities research analysts predict that Cellectis will post -0.46 EPS for the current fiscal year.

Remove Ads

Institutional Trading of Cellectis

Several large investors have recently bought and sold shares of the business. Wells Fargo & Company MN lifted its holdings in shares of Cellectis by 103.4% in the fourth quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company's stock worth $44,000 after acquiring an additional 12,500 shares during the last quarter. Millennium Management LLC acquired a new position in Cellectis during the 4th quarter worth approximately $962,000. Finally, B Group Inc. bought a new position in Cellectis in the 4th quarter valued at approximately $5,547,000. 63.90% of the stock is owned by institutional investors and hedge funds.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.